- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
- Diplomat becomes distributor of recently approved cancer drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Celgene for treating the cancer multiple myeloma, the agency said Friday.
The FDA announced the approval of Pomalyst (pomalidomide) for patients whose disease has progressed after treatment with other cancer drugs.
Multiple myeloma is a form of blood cancer that mostly affects older people and comes from plasma cells in the bone marrow. About 21,700 Americans are diagnosed with it, and 10,710 die every year from the disease, according to the National Cancer Institute.